23andMe to delist from Nasdaq, deregister with SEC

23andMe mentioned it’ll document a Mode 25 Notification of Delisting with the SEC on or round June 6, which might due to this fact take away the keep from checklist and registering with the Nasdaq.

The corporate mentioned the Nasdaq had in the beginning knowledgeable the corporate {that a} Mode 25 could be filed in March, however because the alternate has no longer but submitted the submitting, 23andMe is doing so willingly.

23andMe exploded into the mainstream as a result of its at-home DNA checking out kits that allowed consumers to inspect their genetic profiles. At its height, the corporate was once valued at round $6 billion.

However nearest going folk by means of a merger with a different objective acquisition corporate in 2021, the corporate struggled to generate ordinary income and rise up viable analysis or therapeutics companies.

Regeneron’s offer remains to be topic to favor via the U.S. Chapter Courtroom for the Japanese District of Missouri. Pending favor, it’s anticipated to alike within the 3rd quarter of this month.

WATCH: The be on one?s feet and fall of 23andMe